amyloid/hemorrhage

PRIORITY TO RELATED APPLICATIONS(S) This application claims the benefit of European Patent Application No. 08150173.6, filed Jan. 11, 2008, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

FIELD OF THE INVENTION The present invention relates generally to the field of proteins associated with neural lesions. More specifically, the present invention relates to the detection of protease nexin-2 (hereinafter "PN-2") and other precursors to amyloid deposited in the

The invention relates to the use of compounds (hereinafter: "COMPOUND") or a N-Oxide or a pharmaceutically acceptable salt thereof having an activity on protein kinases VEGFR-2, Tie-2, c-Src, c-Met, FGFR-1, Flt-1, HER-2, c-Abl, c-Raf, PDGFR-beta, c-Kit, or on a combination of the above enzymes, for

FIELD OF THE INVENTION The invention relates to an improved method for preventing or treating vascular hemorrhaging. More specifically, the invention concerns methods for providing improved thrombolytic therapy to individuals who receive such therapy, and for diagnosing and treating diseases, such

FIELD OF THE INVENTION The invention relates to an improved method for preventing or treating vascular hemorrhaging. More specifically, the invention concerns methods for providing improved thrombolytic therapy to individuals who receive such therapy, and for diagnosing and treating diseases, such

BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of

BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life. Pathologically, AD is characterized by the deposition of amyloid in extracellular plaques and intracellular neurofibrillary tangles in the brain. The amyloid plaques are mainly composed of

BACKGROUND OF THE INVENTION This invention relates to inhibitors of beta amyloid production, which have utility in the treatment of Alzheimer's disease. Alzheimer's Disease (AD) is the most common form of dementia (loss of memory) in the elderly. The main pathological lesions of AD found in the

PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No 11156587.5, filed Mar. 2, 2011, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later life.

PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No. 10153843.7, filed Feb. 17, 2010, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

PRIORITY TO RELATED APPLICATION(S) This application claims the benefit of European Patent Application No. 08168719.6, filed Nov. 10, 2008, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

BACKGROUND The prime neuropathological event distinguishing Alzheimer's disease (AD) is deposition of the 40-42 residue amyloid .beta. peptide (A.beta.) in brain parenchyma and cerebral vessels. A large body of genetic, biochemical and in vivo data supports a pivotal role for A.beta. in the

FIELD OF THE INVENTION The present invention relates to novel compounds and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as medicaments for treatment and/or prevention of various diseases. In particular the invention relates to

The present invention relates to compounds and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as medicaments for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which are

The present invention relates to compounds and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as medicaments for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which are